title: Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China.
abstract: BACKGROUND
  Insulin sensitizing drugs such as pioglitazone are not uniformly treatment effective among individual type 2 diabetic patients. Here, the relationship of pioglitazone efficacy to single nucleotide polymorphisms (SNP) of the adiponectin gene, a critical gene directly regulated by the drug, was examined in a cohort of Chinese Han type 2 diabetic patients.
  
  
  METHODS
  Eighty type 2 diabetic patients were treated with pioglitazone (15 mg/day) for 12 weeks without interruption of their current therapeutic regimen. Fasting plasma glucose, fasting insulin, homeostasis model assessment for insulin resistance (HOMA-IR), and glycated hemoglobin (HbA1c%) were collected both prior to and following pioglitazone treatment. Response to pioglitazone was defined as a decrease of at least 15% in HbA1c% levels. Three regions of the adiponectin gene containing SNPs (promoter, intron 2 and exon 2, and exon 3) were amplified and sequenced to determine genotype.
  
  
  RESULTS
  Serum adiponectin levels were significantly increased (p<0.001) whereas fasting plasma glucose, fasting insulin, HOMA-IR, and HbA1c% values were significantly decreased relative to baseline measurements (p<0.001). Response of patients with TG and TT genotypes at rs2241766 (exon2; 52.9% vs. 12.7%, respectively p = 0.001) was statistically significant relative to all other patients. Amongst rs2241766 TG and TT patients, the mean decrease in HbA1c% levels was greater where the genotype was TG (1.15±0.80 vs. 0.52±0.64, p = 0.001).
  
  
  CONCLUSIONS
  The adiponectin gene polymorphism rs2241766 T/G is associated with pioglitazone efficacy in type 2 diabetic patients, and status of the polymorphism may be an important clinical factor to consider prior to pioglitazone treatment.
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yang
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Enling
authors.initials: E
authors.lastname: Ye
authors.affiliation: Department of Endocrinology, Shangdong Jining No. 1 People's Hospital, Jining, Shangdong, China.
authors.forename: Guangxin
authors.initials: G
authors.lastname: Si
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Liangmiao
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Lingqiao
authors.initials: L
authors.lastname: Cai
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Chengfu
authors.initials: C
authors.lastname: Ye
authors.affiliation: Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Chi
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, the Third Hospital Affiliate to Wenzhou Medical University, Ruian, Zhejiang, China; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou, China.
authors.forename: Xuemian
authors.initials: X
authors.lastname: Lu
mesh_terms: D052242:Adiponectin / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D020641:Polymorphism, Single Nucleotide; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone